Metabolon, Inc., a global leader in metabolomics, has started a multi-year collaboration with Merck KGaA, Darmstadt, Germany, a leading company in the field of science and technology . Merck KGaA, Darmstadt, Germany carries out biopharmaceutical activities in the USA and Canada under the name EMD Serono.

As an exploratory metabolomics partner, Metabolon will support clinical and translational research projects in the various therapeutic areas. The agreement will be effective from August 3, 2020.

"We are delighted that Merck KGaA, a globally specialized biopharmaceutical innovator, has selected Metabolon to facilitate the further advancement of the important work it does to bring innovative therapies to patients," said Michael Rasche , President and General Manager of the business. Metabolon International. "We believe that our exclusive Precision Metabolomics ™ solution will provide Merck KGaA Darmstadt, Germany with usable insights for decision making, enabling new discoveries in the early stages of drug development programs. The conclusion of this long-term agreement represents another recognition. important to Metabolon as a first-class supplier of metabolomics solutions. "

The metabolomics reflects the biochemical activity in the cells, representing the real-time interaction of a system with more precise treatment than more traditional technologies. This real-time and in vivo vision provides drug developers with a global way of mapping the characteristics of the model system, helping to speed up the decision-making process thanks to a greater understanding of the mechanism of action and the identification of biopharmaceutical biomarkers, response and effectiveness.

As part of the collaboration, Metabolon will perform complete metabolomics analyzes, providing biological interpretation and analysis of results to shed light on the biomarkers and biochemical pathways observed, in order to improve the speed and results of Merck's pharmaceutical development pipeline. KGaA's, Darmstadt, Germany.

The metabolomics

The metabolomics allows you to understand biology, health, well-being and disease. All biological systems, including humans, continuously feed a series of chemical reactions. Essentially, metabolomics is the large-scale study of small molecules, called metabolites, which form the metabolome. This science reveals the definitive representation of the phenotype of any biological system, measuring the contributions of internal and external factors, such as health, disease, nutrition, microbiome, medicines, pollution, etc. While innovation in other life sciences slows down, metabolomics is establishing itself as a new frontier to support research bodies in the study of the influence that genes, microbiomes, food,

Metabolon

Metabolon, Inc., is a global leader in the discovery of new biological knowledge thanks to the metabolomics and power of the Precision Metabolomics ™ platform that allows it to deepen its biological understanding of pathological states and physiological reactions in the present. The company offers scalable and customizable metabolomics solutions, from discovery to clinical trials, to product life cycle management. With one of the largest and most diverse collections of patient data in the world, Metabolon has the tools necessary to provide biologically relevant knowledge to answer some of the most urgent and difficult questions in the life sciences field, helping to accelerate research and development successful products in the biopharmaceutical sectors, population health, consumer products, well-being and academic research. The company was founded in 2000 and is based inResearch Triangle Park in North Carolina , as well as having an international office in Munich , Germany. For more information visit www.metabolon.com  or follow us on  LinkedIn  or  Twitter .

 

Source:prnewswire.com

Report Abuse